with program directors in NIGMS to determine the most
appropriate support mechanism for their collaborative
work.

Term/Amount: NIGMS intends to commit up $10-15
million in total costs in FY2002 to fund both Phase I and
Phase II awards. NIGMS anticipates funding up to ten
Phase I awards; each Phase I award will be for $25,000 in
direct costs. Two to three Phase II grants will be awarded.
Because the nature and scope of the proposed research will
vary, it is anticipated that the size of the Phase II awards
also will vary, and the upper limit for a Phase II award will
be $5 million per year in annual direct costs. Applications
of different scales and scope are encouraged. Although the
financial plans of NIGMS provide support for this pro-
gram, awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number
of meritorious applications

Contact: The RFA label available in the PHS 398 (rev.
4/98) application form must be affixed to the bottom of the
face page of the application. Type the RFA number on the
label. Failure to use this label could result in delayed
processing of the application such that it may not reach the

review committee in time for review. In addition, the RFA
title and number must be typed on line 2 of the face page
of the application form and the YES box must be marked.
The sample RFA label available at: http://grants.nih.gov/
grants/funding/phs398/label-bk.pdf has been modified to
allow for this change. Please note this is in pdf format.
Submit a signed, typewritten original of the application
(Phase I or Phase II), including the Checklist, and three
signed, photocopies, in one package to: CENTER FOR
SCIENTIFIC REVIEW NATIONAL INSTITUTES OF
HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040,
MSC 7710 BETHESDA, MD 20892-7710 BETHESDA,
MD 20817 (for express/courier service). Direct inquiries
regarding programmatic issues to: Dr. Michael E. Rogers
Division of Pharmacology, Physiology and Biological
Chemistry National Institute of General Medical Sciences
45 Center Drive, MSC 6200 Bethesda, MD 20892-6200
Telephone: (301) 594-3827 FAX: (301) 480-2802 Email:
rogersm@nigms.nih.gov

Deadline: Phase I Application Receipt Date: June 18,
2001. Phase II Application Receipt Date: January 16,
2002.

ERRATA

In abstract 231, “Back to Basics: Utility of Peripheral Smears in Residency Training,” on page 43A of the January 2001
issue of JIM, the name of the first author, Amish Desai, was inadvertently left out. The authors apologize for the omission.

In the January 2001 issue of JIM, seven abstracts from the Southern Society of General Internal Medicine were
inadvertantly left out. These abstracts are printed in this issue of JIM on the following pages. The publisher regrets the
error.

302 Journal of Investigative Medicine • Vol. 49, No. 3, May 2001

 o
n

 A
p
ril 5

, 2
0
2
1

 b
y g

u
e

st. P
ro

te
cte

d
 b

y co
p
yrig

h
t.

h
ttp

://jim
.b

m
j.co

m
/

J In
ve

stig
 M

e
d

: first p
u

b
lish

e
d

 a
s 1

0
.2

3
1

0
/6

6
5

0
.2

0
0

1
.3

4
0
0
4
 o

n
 1

0
 D

e
ce

m
b
e
r 2

0
1
5
. D

o
w

n
lo

a
d
e
d
 fro

m
 

http://jim.bmj.com/